(±)-Naringenin (50 mg/kg, orally, once a day for ten days) significantly reduces the severity of DSS-induced colitis in mice and downregulats pro-inflammatory mediators (iNOS, ICAM-1, MCP-1, Cox2, TNF-α, and IL-6 mRNA) in the colonic mucosa[2].
| Animal Model: | C57BL/6[2] |
| Dosage: | 50 mg/kg |
| Administration: | Oral; daily; 10 days |
| Result: | Reduced the severity of DSS-induced colitis in mice, downregulated pro-inflammatory mediators (iNOS, ICAM-1, MCP-1, Cox2, TNF-α, and IL-6 mRNA) in the colonic mucosa, inhibited the increase in TLR4 mRNA and protein levels, and reduced the phosphorylated NF-κB p65 protein level. |
